Cerebral palsy: not always what it seems

R Gupta, R E Appleton

Cerebral palsy (CP) is an umbrella term that defines a group of non-progressive, but often changing, syndromes of motor impairment secondary to lesions or anomalies of the brain arising in the early stages of its development. The characteristic clinical feature that is common to all CP syndromes is the presence of pyramidal or extrapyramidal signs. CP is neither a specific disease nor a pathological or aetiological entity, and importantly the term CP does not—and should not—necessarily imply or identify a specific cause. The prevalence of CP ranges from 1.5 to 2.5 per 1000 live births, with the risk highest among very preterm and low birthweight babies. However, the majority of children with CP are born at or near term gestation. Causes of CP include perinatal hypoxic-ischaemic encephalopathy, intra- or periventricular haemorrhage, cerebral dysgenesis, and intracranial infection. The CP syndromes may be classified by the predominant type of motor disturbance, including, for example, diplegia, tetraplegia, hemiplegia, dyskinesia, and ataxia, although frequently the overall clinical picture is not always pure. Finally, the aetiologies for these different syndromes tend to be quite distinct.

Once a diagnosis of CP has been made on the basis of the child’s symptoms and signs, each child should undergo appropriate evaluation and investigation to try and establish a cause and specifically to determine whether it is of prenatal, perinatal, or postnatal origin. Investigation is indicated even when there has been evidence of a preceding neurological event during the perinatal period or infancy, because some of these children may have an underlying neurological or metabolic disorder which may have made them more vulnerable to the stresses of delivery and extrauterine life. Finally, it is important that all children with a diagnosis of CP should be followed up, and when no obvious cause has been identified or there is any evidence of regression, children should be referred to a paediatric neurologist.

A number of neurodegenerative, including metabolic and genetic disorders may present with similar symptoms and signs. Some of these disorders which are slowly progressive are more likely to be misdiagnosed as CP. Individually these disorders may be rare, but collectively they are not. It is important that these disorders are correctly diagnosed as early as possible for a number of reasons. Firstly, some may be treatable; secondly, the family can be provided with more accurate information regarding the prognosis; and finally, genetic counselling may be offered, including, where appropriate, prenatal testing. Table 1 lists the more common diseases which have not infrequently been misdiagnosed as CP, both in our experience and that of others. This is not a comprehensive list.

### Apparent muscle weakness

Muscle weakness does not occur in CP, but not uncommonly the profound hypotonia seen in children with CP in the first year of life is misinterpreted as weakness. Genuine muscle weakness implies a peripheral neuromuscular component including an anterior horn cell disorder, a peripheral neuropathy or a myopathy, or a defect in neuromuscular transmission. However, children aged 2 years and over with evolving CP will also have clonus and exaggerated deep tendon reflexes (DTRs) in the lower limbs. Some disorders, including metachromatic leucodystrophy, infantile neuroaxonal dystrophy and a variety of muscular dystrophies, may present with mild hypotonia in early infancy.

### Table 1 The more common disorders which may be misdiagnosed as cerebral palsy (listed alphabetically)

<table>
<thead>
<tr>
<th>With apparent or real muscle weakness</th>
<th>With predominant diplegia/tetraplegia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duchenne/Becker muscular dystrophy</td>
<td>Adrenoleucodystrophy, <em>adrenomyeloneuropathy</em></td>
</tr>
<tr>
<td>Infantile neuroaxonal dystrophy</td>
<td>Arginase deficiency</td>
</tr>
<tr>
<td>Mitochondrial cytopathy</td>
<td>Hereditary progressive spastic paraplegia</td>
</tr>
<tr>
<td></td>
<td>Holocarboxylase synthetase deficiency</td>
</tr>
<tr>
<td></td>
<td>Metachromatic leucodystrophy</td>
</tr>
<tr>
<td>With significant dystonia involuntary movements</td>
<td>With significant ataxia</td>
</tr>
<tr>
<td>Dopa responsive dystonia</td>
<td>Angleman syndrome</td>
</tr>
<tr>
<td>Glutaric aciduria type 1</td>
<td>Ataxia telangiectasia</td>
</tr>
<tr>
<td>Juvenile neuronal ceroid lipofuscinosis</td>
<td>Chronic/adult GM 1 gangliosidosis</td>
</tr>
<tr>
<td>Lesch–Nyhan syndrome</td>
<td>Mitochondrial cytopathy (specifically due to the NARP mutation)</td>
</tr>
<tr>
<td>Pelizaeus–Merzbacher disease</td>
<td>Niemann–Pick disease type C</td>
</tr>
<tr>
<td>Pyruvate dehydrogenase deficiency (and other mitochondrial cytopathies presenting with a Leigh syndrome phenotype)</td>
<td>Pontocerebellar atrophy/hypoplasia (in isolation or as part of the carbohydrate glycoprotein deficiency syndrome)</td>
</tr>
<tr>
<td>Rett syndrome</td>
<td>Posterior fossa tumour</td>
</tr>
<tr>
<td>3-methylglutaric aciduria</td>
<td>X linked spinocerebellar ataxia</td>
</tr>
<tr>
<td>3-methylcrotonyl CoA carboxylase deficiency</td>
<td></td>
</tr>
</tbody>
</table>
dystrophy, and the pontocerebellar atrophies, frequently show simultaneous central and peripheral nervous system involvement, and may lead to an initial diagnosis of CP.

**Duchenne muscular dystrophy** (DMD) usually presents with delayed independent walking and an awkward and often tiptoe gait. This presentation, particularly if accompanied by non-motor developmental delay, as occurs in ataxia, particularly if accompanied by non-peripheral nervous system involvement, and may frequently show simultaneous central and peripheral neuropathy. Signs and symptoms are often present in other family members and should be specifically sought. Inheritance may be X linked, autosomal dominant (commonly in the “pure” form) or recessive, and spontaneous mutations may also occur.

**Holocarboxylase synthetase deficiency** usually presents in infancy with severe metabolic acidosis. Erythematous scaly skin eruptions, developmental delay, and hypertonia have been described in these patients. All patients are sensitive to treatment with biotin; the clinical response to treatment is dramatic, with resolution of the skin rash and the organic aciduria. Diagnosis is confirmed by finding raised concentrations of lactate, 3-methylcrotonylglycine, and 3-hydroxyisovaleric acid in the blood and urine.

**With significant dystonia/involuntary movements**

Dystonia and involuntary movements (specifically choreoathetosis) are not as common in CP as is generally believed. If present in CP, these features typically occur following a short but profound period of hypotension and hypoxia in the perinatal period.

**Dopa responsive dystonia** (DRD) may mimic athetoid or dyskinetic CP. Dystonia, usually affecting the legs, which usually worsens throughout the day, occurs in early childhood or, less commonly, in adolescence. The abnormal gait is often quite bizarre and may initially be interpreted as psychogenic in origin or “hysterical”. The gait disturbance usually shows a dramatic and sustained response to small doses of levodopa. A trial of levodopa should be used in all children who present with dystonia. In the differential diagnosis, Wilson disease should be considered when orofacial dystonia accompanies limb dystonia in children over 8 years of age, and idiopathic torsion dystonia when the dystonia is asymmetric and develops after 10 years of age.

**Glutaric aciduria type I**, an autosomal recessive condition, results from a failure to metabolise lysine, hydroxylysine, and tryptophan. The disease usually presents in late infancy, either with mild, global developmental delay and a relative macrocephaly or with an acute encephalopathy in the first two years of life. Some children present later with dystonia and choreoathetosis. Diagnosis is confirmed by showing raised concentrations of glutaric acid and 3-hydroxyglutaric acid on urine organic acid analysis. Occasionally these concentrations may be low and the diagnosis can be confirmed by measuring activity of the enzyme glutaryl CoA dehydrogenase in cultured fibroblasts. Dietary and pharmacological treatment may modify the course of the disease.

**Pyruvate dehydrogenase complex deficiency** is a common cause of lactic acidosis; in most cases...
it is caused by mutations in the X linked gene coding for the E1α subunit of this mitochondria
enzyme complex. Pyruvate and alanine concentrations may also be raised in urine, blood, and cerebrospinal fluid. The clinical presentation is variable. The most severe presentation is of infantile acidosis, resulting in death by 6 months of age. Patients with less notable but more chronic lactic acidosis, often have clinical and neuropathological features of Leigh syndrome. They may have dystonia, spastic tetraparesis, microcephaly, mental retardation, and epilepsy. MRI commonly shows symmetrical lesions in the basal ganglia, thalami, and brain stem. Children may show rapid deterioration or episodic stepwise deterioration following infections. Leigh syndrome may be caused by abnormalities in the mitochondrial respiratory chain enzymes, including pyruvate carboxylase deficiency, biotinidase deficiency, fumarase deficiency, sulphite oxidase deficiency, and 3-methylglutaconic aciduria.

Lesch–Nyhan disease is an X linked recessive condition presenting in the first year of life. Following normal or near normal development for the first six months, children then rapidly develop spasticity, choreoathetosis, and notable learning difficulties. Behavioural problems, including severe irritability and self mutilation (of lips and fingers) are also common. The disorder is caused by absence or notable deficiency of the enzyme hypoxanthine guanine phosphoribosyltransferase, resulting in hyperuricaemia and high concentrations of uric acid in the urine. Orange urate crystals in the nappies may be the first recognised “sign”. Partial deficiency of the enzyme results in a milder clinical phenotype.

Rett syndrome, a slowly progressive disorder of development in girls, is characterised by choreoathetosis, spasticity, autistic traits, seizures, an abnormal respiratory pattern, acquired microcephaly, and loss of purposeful hand function. The latter results in the characteristic stereotyped and often continuous hand wringing action of these girls. Development may appear to be normal or near normal until the age of 6–18 months. The diagnosis can now be confirmed by enzyme assay in leucocytes or cultured fibroblasts.

Juvenile neuronal ceroid lipofuscinosi presents after 5 years of age with slowly progressive loss of cognitive abilities, epilepsy, extrapyramidal signs, rigidity, and visual failure. The diagnosis may be confirmed by showing the characteristic inclusion bodies in lymphocytes or cultured fibroblasts.

Pelizaeus–Merzbacher disease is a slowly progressive X linked leucodystrophy with mixed pyramidal and extrapyramidal manifestations, resulting from a deficiency of a myelin protein, proteolipid protein. It presents in the first year (often months) of life with characteristic pendular nystagmus (never seen in CP), notable involuntary movements (choreoathetosis), a spastic tetraparesis, and relatively intact intellect, although the latter may be difficult to appreciate because of the involuntary movements of the limbs and orofacial muscles. Inspiratory stridor is a relatively common and additional characteristic feature and may occur at any stage of the disease. The nystagmus tends to resolve in later childhood. Diagnosis is made by showing notably delayed cerebral myelination on MRI, abnormal visual evoked potentials, or, more definitively, by DNA analysis.

3-Methylglutaconic aciduria is an autosomal recessive disorder characterised by increased urinary excretion of 3-methylglutaric and 3-methylglutaconic acids. It most commonly affects families of Iraqi–Jewish origin, and is manifest by involuntary movements, ataxia, spasticity, and, less commonly, optic atrophy. 3-Methylcrotonyl CoA carboxylase deficiency presents with notable growth retardation, profound mental retardation, epilepsy, spastic tetraplegia, opisthotonic dystonia, gastroesophageal reflux, and recurrent episodes of aspiration pneumonia. The diagnosis is confirmed by enzyme assay in leucocytes or cultured fibroblasts.

With significant ataxia Ataxia may be difficult to recognise in the first year of life and may initially present as profound truncal hypotonia and delay in achieving fine and gross motor milestones. Not uncommonly ataxia coexists with involuntary movements, including, for example, myoclonus in Angelman’s syndrome.

Ataxia telangiectasia (AT) presents in the first three years of life with repeated respiratory tract infections and is accompanied by progressive spasticity and dysarthria. The characteristic conjunctival and ear telangiectases develop later (after the age of 4 years). AT may be diagnosed by high concentrations of serum α fetoprotein, low serum IgA concentrations, or by DNA analysis.

Chronic/adult GM 1 gangliosidosis storage disease may present with progressive cerebellar dysarthria, ataxia, myoclonus, and spasticity. Intellectual impairment may be mild and dystonia may be a prominent feature. Fundoscopy may reveal cherry red spots. Diagnosis may be confirmed by showing reduced β galactosidase in leucocytes.

X linked spinocerebellar ataxia may present with spastic diplegia; additional clinical features may include nystagmus, ataxia, pyramidal signs, dysarthria, and learning difficulties.

Pontocerebellar atrophies/hypoplasias are a group of disorders which may present at or soon after birth, childhood, adolescence, or adult life. A number are associated with the carbohydrate deficient glycoprotein (CDG) syndromes or with anterior horn cell involvement, or both. Those children who survive the first year of life usually present with a slowly progressive ataxia, dysarthria, and predominantly distal muscle wasting. Diagnosis is based on MRI findings, electromyography, and biochemical analysis (for example, isoelectric focusing of sialotransferrins in some of the associated CDG syndromes phenotypes).

Niemann–Pick disease type C is an autosomal recessive condition which presents neurologically between the ages of 2 and 12 years, with
Cerebral palsy

tremor, clumsiness, ataxia, poor concentration, vertical supranuclear ophthalmoplegia, dysarthria, and dystonia. Seizures may develop and the neurological dysfunction is progressive. Ultimately, there is complete loss of vertical eye movements involving both upward and downward gaze, which, occurring on a background of progressive neurological deterioration is almost pathognomonic of this disorder. The initial presentation is commonly in the first year of life, with failure to thrive and hepatosplenomegaly. The diagnosis is established by showing sea blue histiocytes in bone marrow or by impaired cholesterol esterification on cultured fibroblasts and the positive filipin test for accumulation of free cholesterol.

Mitochondrial cytopathies, specifically caused by the 8993 mutation causing neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) may also be misdiagnosed as “familial CP”; CP caused by a perinatal insult such as periventricular leucomalacia or hypoxic encephalopathy rarely recurs in families. “Familial CP” should always raise the possibility of an underlying genetic disorder, including a number of metabolic diseases.

With significant bulbar and oromotor dysfunction

Bulbar and oromotor dysfunction, including speech and feeding difficulties, are not uncommon in CP, but tend to be less severe than the more prominent motor and mobility difficulties.

Würster-Drought syndrome (also called the bilateral perisylvian or opercular syndrome) describes a supranuclear (pseudobulbar) palsy that presents with sucking and swallowing difficulties, excessive salivation, severe dysarthria, and an exaggerated jaw jerk. Children also usually show either a mild spastic diplegia or ataxia, variable cognitive and behavioural impairment, and epilepsy. The condition may be congenital or acquired; MRI usually shows abnormalities of the opercular cortex, with dysgenesis (including defects of neuronal migration) of the perisylvian region in the congenital form.

Conclusions

Cerebral palsy is a neurological syndrome and refers to a combination of signs and symptoms; it is not a disease. It encompasses a group of non-progressive, but often changing, motor impairment syndromes secondary to lesions or anomalies of the brain, arising in the early stages of its development. A number of symptoms and signs are common to both CP and neurodegenerative/metabolic disorders, particularly in infancy and early childhood. All children with features of CP should be carefully evaluated for an underlying cause, particularly in the following situations:

- Absence of a definite preceding perinatal insult
- Presence of a positive family history of “cerebral palsy”
- Occurrence of developmental regression (loss of abilities)

- Presence of oculomotor abnormalities, involuntary movements, ataxia, muscle atrophy, or sensory loss.

Investigations should then be determined on an individual basis, depending on the history and clinical findings, and looking particularly for those metabolic disorders that can be identified by blood and urine amino acid analysis, urine organic acid analysis, and measurement of white blood cell enzymes. However, it is the authors’ belief that MRI of the brain and brainstem should be undertaken in all children with features of CP. Ideally, MRI should be performed at 2–3 years of age, when it is easier to assess cerebral myelination or identify any subtle cerebral dysgenesis, although earlier brain imaging may be appropriate in children who have congenital microcephaly, who are dysmorphic, or who have evidence of either a congenital or early onset hemiplegia. Neuroimaging may also provide radiological evidence to support a history of a perinatal neurological insult, or it may suggest an alternative cause for the child’s neurological findings.

Finally, there should be a low threshold for referring children to a paediatric neurologist or a clinical geneticist, or both if appropriate. This should be determined by the clinical history and examination findings and the experience of the general paediatrician. Evidence of a family history of “cerebral palsy”, progressive neurological signs, and/or regression are absolute indications for a paediatric neurological assessment.

Cerebral palsy: not always what it seems

R Gupta and R E Appleton

Arch Dis Child 2001 85: 356-360
doi: 10.1136/adc.85.5.356

Updated information and services can be found at:
http://adc.bmj.com/content/85/5/356

These include:

References
This article cites 28 articles, 6 of which you can access for free at:
http://adc.bmj.com/content/85/5/356#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Rheumatology (521)
- Child health (3922)
- Cerebral palsy (147)
- Metabolic disorders (761)
- Clinical genetics (49)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/